Ceritinib is a kinase inhibitor indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib; however, the efficacy of ceritinib in patients with untreated ALK-rearranged NSCLC is unknown.